Gastrointestinal (GI) tract, cancer is a collective term used to represent cancers that affect the digestive system. Worldwide, the most commonly diagnosed GI tract cancers include: Gastric cancer, Colorectal cancer, Esophageal cancer, Pancreatic cancer and Liver Cancer. GITCandb is a specialized and comprehensive database dedicated to GI tract cancers, offering an extensive range of information on various aspects of these cancers. It houses a large collection of manually curated genes, which have been identified through advanced machine learning techniques specifically for GI tract cancer types such as esophageal, gastric, liver, colorectal, and pancreatic cancers. These genes are linked to important cancer-related processes, providing valuable insights for research and clinical applications. The database also includes detailed information on biomarkers associated with these cancers, including relevant literature, sources, and their regulatory mechanisms, which are crucial for understanding cancer pathogenesis and progression. Researchers and clinicians utilize GITCandb as an essential resource to explore genes and biomarkers that could contribute to innovative cancer research. It provides a platform for identifying potential therapeutic targets, as well as understanding the molecular underpinnings of GI tract cancers. Additionally, the database offers regulatory networks, with properties and calculations related to gene interactions. A powerful prediction tool, accessible via an external GitHub link, enables users to perform gene expression analysis, facilitating predictive modeling of cancer-related outcomes. GITCandb is a web-accessible and comprehensive open resource for providing the resource, including biomarker identification in GI Tract cancers, predicting GI-Tract cancers, gene regulatory network and differential expression analysis of genes of different GI tract cancer.

In 2022 over 22 million new cases were diagonosed across the worldwide and approximately 9.7 million cancer death occured. In 2050, these numbers will rise to an expected 35 million new cases and 17.5 million cancer deaths if our ability to prevent, diagonose and treat cancer does not improve.